Press & Announcements

Press & Announcements
  • CANTON, Mass. – May 22, 2017
    Organogenesis Closes on a $20 Million Facility from Eastward Capital Partners
    Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, today closed a $20 million financing facility with Eastward Capital Partners, a leading provider of venture debt and equity financing to technology companies.
    (Read full version of this press release...)
  • CANTON, Mass. – April 10, 2017 /PRNewswire/
    Organogenesis Secures $25M Credit Facility from Silicon Valley Bank
    Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, has entered into a revolving line of credit agreement with Silicon Valley Bank (SVB), the bank of the world's most innovative companies and their investors. This agreement provides $25 million of new capital to the company to be used for working capital and general corporate purposes.
    (Read full version of this press release...)
  • CANTON, Mass. – April 6, 2017
    Organogenesis Shares Successes and Best Practices for Cell-Based Product Manufacturing at the 6th Stem Cell Product Development and Commercialization Conference
    Company’s Senior Vice President of Quality Speaks at Expert Panel On Manufacturing and Scalable Processes
    Stem cell scientists, researchers and product developers will learn more about Organogenesis’ state-of-the art manufacturing process and successful commercial-scale production of FDA-approved wound healing therapies at the 6th Stem Cell Product Development and Commercialization Conference held April 6-7 in Boston, Massachusetts. The conference highlights cutting-edge developments in all areas of stem cell research, including the biology, medicine, applications and regulation of stem cells.
    (Read full version of this press release...)
  • Canton, Mass / San Diego, CA – April 6, 2017
    Organogenesis Celebrates Product Acquisitions; Highlights New Research at SAWC Spring 2017
    This week, during the 30th Annual Symposium on Advanced Wound Care Spring|Wound Healing Society meeting (SAWC Spring|WHS), Organogenesis will celebrate company milestones – including the recent acquisition of NuTech Medical and the three-year anniversary of the Dermagraft® acquisition – and highlight new products and research at the nation’s largest interdisciplinary wound care forum, held April 5-9 in San Diego.
    (Read full version of this press release...)
  • Canton, MA / Birmingham, AL – March 28, 2017
    Organogenesis Inc. Announces Acquisition of NuTech Medical
    Acquisition Creates Regenerative Medicine Powerhouse in Wound Care, Orthopedic and Surgical Markets
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, is expanding beyond wound care with the acquisition of NuTech Medical. The newly-combined company will offer a portfolio of advanced and next generation products for the wound care and surgical biologics markets.
    (Read full version of this press release...)
  • CANTON, Mass. – March 27, 2017
    Organogenesis Announces Launch of PuraPly™ Antimicrobial Clinical Research Program
    Multi-site, prospective studies, and a patient registry, commence across the country with a total of 440 patients to be enrolled
    Organogenesis Inc., a global leader in advanced wound care innovations and technologies, today announced the launch of a PuraPly™ Antimicrobial (PuraPly™ AM) clinical research program which will comprise multiple studies and a nationwide patient registry.
    (Read full version of this press release...)
  • CANTON, Mass. – January 4, 2017
    Apligraf® is First Wound Healing Therapy to Demonstrate Significant Change in Chronic Wound’s Genomic Profile
    - New Research Evaluating Apligraf’s® Role in Converting Chronic Wound Environment into Acute Healing Profile Published in Science Translational Medicine -
    (Read full version of this press release...)
  • CANTON, Mass. – December 14, 2016
    PuraPly™ and PuraPly Antimicrobial (AM)™ Receive Permanent Q-Code, Expanding Medicare Coverage After January 1 to Include Treatment in Private Physician Office Setting
    PuraPly Products Retain Pass-Through Reimbursement Status Throughout 2017
    Organogenesis Inc., a global leader in advanced wound care innovations and technologies, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned permanent Q-codes for its PuraPly™ and PuraPly Antimicrobial (AM)™ wound management products.
    (Read full version of this press release...)
  • CANTON, Mass. – November 21, 2016
    Congressman Joe Kennedy III Tours Massachusetts-Based Biotech Firm Organogenesis Inc.
    -Global Leader in Advanced Wound Care Showcases Industry-Leading Products, R&D Laboratories, Manufacturing Facilities-
    U.S. Representative Joe Kennedy III (MA-4) today visited the Canton, Mass. headquarters of Organogenesis Inc., a global leader in advanced wound care innovation and technologies, to tour its research and development labs and manufacturing facilities, meet with employees, and learn about biotechnology solutions that are improving the lives of millions of Americans battling non-healing, chronic wounds like diabetic foot ulcers (DFUs).
    (Read full version of this press release...)
  • CANTON, Mass. and LAS VEGAS, Nev. ‐ Oct. 6, 2016
    Organogenesis’ Advanced Wound Care Portfolio Highlighted at SAWC Fall 2016
    This week, new data and information featuring Organogenesis’ FDA-approved bioengineered cell-based products Apligraf® and Dermagraft®, and wound management products PuraPly™ and PuraPly Antimicrobial (AM)™ will be presented at the Fall Symposium on Advanced Wound Care (SAWC), the nation’s largest interdisciplinary wound care forum, held October 7-9, 2016 in Las Vegas.
    (Read full version of this press release...)
  • Canton, Mass – September 19, 2016
    Organogenesis Announces New Chief Financial Officer
    Tim Cunningham has been appointed Chief Financial Officer of Organogenesis Inc., President and CEO Gary S. Gillheeney, Sr. announced today.
    (Read full version of this press release...)
  • Canton, Mass – September 12, 2016
    Nation's Leading Developer of Advanced Wound Care Technologies Urges FDA to Finalize Regulatory Guidance to Ensure Safety and Efficacy of Section 361 HCT/Ps
    Organogenesis Inc., a global leader in FDA-approved and FDA-cleared advanced wound care innovation and technologies, today urged the U.S. Food and Drug Administration (FDA) to finalize two draft guidance documents that would clarify the existing regulatory criteria for determining if products qualify for regulation solely as Section 361 Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) – and in doing so, bring needed regulatory oversight to the wound care industry.
    ( Read full version of this press release...)
  • Canton, Mass – August 26, 2016
    Advanced Wound Care Products PuraPly™ and PuraPly Antimicrobial™ Now Available for Medicare Reimbursement in 10 Additional States
    -Decision by National Government Services to Retire Policy on Application of Cellular or Tissue Based Products Effective September 1, 2016 -
    Organogenesis, a global leader in advanced wound care innovations and technologies, today announced that its PuraPly™ and PuraPly Antimicrobial (AM)™ wound management products are now eligible for Medicare coverage and reimbursement in 10 additional states, providing coverage for an additional 7.5 million Medicare beneficiaries, following the decision by National Government Services (NGS) to retire its local coverage determination (LCD) for cellular and tissue-based products (CTPs) effective September 1, 2016.
    ( Read full version of this press release...)
  • Canton, Mass – May 18, 2016
    New Research Highlights Ability of PuraPly™ and PuraPly Antimicrobial (AM)™ to Manage Bioburden and Support Healing Across Variety of Wound Types
    Three new research abstracts presented at the recent 2016 Symposium on Advanced Wound Care (SAWC) highlight the role of PuraPly™ and PuraPly Antimicrobial (AM)™ – two new FDA-cleared collagen matrix products from Organogenesis Inc. – in managing bioburden and supporting wound healing across a variety of wound types.
    ( Read full version of this press release...)
  • Canton, Mass – May 11, 2016
    Award-Winning Research from the University of Miami Evaluates Apligraf’s® Role in Reversing a Chronic Wound Environment
    Award-winning research from a multidisciplinary team at the University of Miami provides new insight on what happens to a patient’s genomic profile when Apligraf®, an FDA-approved, bioengineered living cell-based therapy from Organogenesis Inc., is applied to a chronic venous leg ulcer (VLU), when compared to conventional therapy alone. The analysis found that Apligraf altered specific molecular and cellular responses in the wound environment, reversing the chronic wound profile to resemble more of an acute wound profile.
    ( Read full version of this press release...)
  • Canton, Mass / San Diego, CA – April 14, 2016
    Organogenesis Secures $30 Million in Financing to Fund Aggressive Expansion of Commercial Operations and Product Portfolio
    Organogenesis Inc. - a global leader in advanced wound care innovation and technologies – has raised approximately $30 million in capital from existing investors to support a significant expansion of the company’s commercial operations, sales force, PuraPly product line, and new product development in the wound care and surgical fields.
    ( Read full version of this press release...)
  • Canton, Mass / Atlanta, GA – April 14, 2016
    Organogenesis’ Expanding Wound Care Portfolio Featured in Eight New Presentations This Week at SAWC/WHS Spring 2016
    This week, new data featuring Organogenesis’ bioengineered cell-based wound healing products Apligraf® and Dermagraft®, and the wound management products PuraPly™ and PuraPly Antimicrobial (AM)™, will be presented at the Symposium on Advanced Wound Care (SAWC) / Wound Healing Society (WHS) Spring Meeting, the leading national wound healing conference being held in Atlanta, Georgia.
    ( Read full version of this press release...)
  • Canton, Mass / Manassas, Virg. – November 24, 2015
    Department of Veterans Affairs Expert Holds Diabetes Awareness Month Educational Webinar for Veterans on Diabetic Foot Care and Limb Loss Prevention
    As part of Diabetes Awareness Month, the Amputee Coalition and Organogenesis Inc. convened an educational webinar for U.S. Veterans, their families, caregivers, and clinicians on preventing limb loss for patients battling diabetes. The webinar comes at a time when nearly half of the U.S. population is diabetic or pre-diabetic and the rate of diabetic patients at the Veterans Health Administration is around 25 percent.
    ( Read full version of this press release...)
  • Canton, Mass / Reinach, Switzerland – November 2, 2015
    Apligraf® Wound Healing Technology Becomes First Transplant Product to Receive Marketing Approval in Switzerland
    Organogenesis Inc. today announced that its Apligraf® wound-healing technology has become the first transplant product in Switzerland to receive marketing authorization from Swissmedic for the treatment of venous leg ulcers (VLU) and diabetic foot ulcers (DFU). In Switzerland, the classification of "transplant products" includes cell therapies such as Apligraf.
    ( Read full version of this press release...)
  • Canton, Mass – October 8, 2015
    Comparative Effectiveness Analyses Report Faster Healing Times, Improved Probability of Chronic Wound Closure with Apligraf® and Dermagraft®
    Three new real-world, comparative effectiveness analyses reporting the clinical outcomes of Apligraf® for the treatment of hard-to-heal venous leg ulcers (VLUs), and Dermagraft® for the treatment of chronic diabetic foot ulcers (DFUs), were recently presented at the Fall Symposium for Advanced Wound Care (SAWC) annual medical meeting in Las Vegas, Nev. Apligraf® and Dermagraft® are the only living cell-based products in the "skin substitute" category to have received FDA approval for chronic wound healing. They are both manufactured by Organogenesis Inc., a global leader in regenerative medicine for wound healing.
    ( Read full version of this press release...)
  • Canton, Mass/Las Vegas, Nev. – September 24, 2015
    Organogenesis to Feature Comparative Effectiveness Analyses and New Products at SAWC Fall 2015
    This week Organogenesis Inc. will highlight its growing portfolio of advanced wound care products and present the results of real-world, comparative effectiveness analyses, demonstrating the effectiveness of its Apligraf® and Dermagraft® living cell-based therapies, compared to Epifix, Primatrix and Theraskin, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, being held September 26-28, 2015 in Las Vegas, Nev.
    ( Read full version of this press release...)
  • ORLANDO, FL. – July 29, 2015
    At APMA: "Shifting the Antimicrobial Paradigm" non-CECH Presentation Examines PuraPly AM
    ( Read full version...)
  • ORLANDO, FL. – July 22, 2015
    Organogenesis Launches New PuraPly™ Products at the APMA 2015 Annual Scientific Meeting
    This week at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, Organogenesis Inc. will launch its new PuraPly™ wound management products. This includes the launch of PuraPly Antimicrobial (PuraPly AM), the first Food and Drug Administration (FDA)-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent.
    ( Read full version of this press release...)
  • CANTON, MASS. – June 22, 2015
    Landmark New Data: Apligraf® Closes Significantly More Diabetic Foot Ulcers in Half the Time When Compared to Epifix
    A new real-world comparative effectiveness analysis, published online this week in the peer-reviewed journal Wound Repair & Regeneration, reported that Apligraf® has demonstrated improved outcomes over Epifix by a wide margin. The large-scale analysis, the first of its kind, examined healing rates of patients with diabetic foot ulcers (DFUs) who were treated either with Organogenesis' Apligraf® or with Epifix, made by MiMedx Group, Inc.
    ( Read full version of this press release...)
  • CANTON, MASS. – March 26, 2015
    Journal of Medical Economics Publishes Findings from Groundbreaking Research Demonstrating the Health Economic Benefits of Apligraf® and Dermagraft®
    Organogenesis Inc., a world leading regenerative medicine company, announced publication of groundbreaking new data demonstrating significantly improved outcomes and economic benefits of both Apligraf® and Dermagraft® in the treatment of diabetic foot ulcers (DFUs) in the peer-reviewed Journal of Medical Economics.
    ( Read full version of this press release...)
  • CANTON, MASS. – February 4, 2015
    Organogenesis Announces MiMedx Has Dismissed its Frivolous Lawsuit
    Organogenesis Inc., a world leading regenerative medicine company, announced today that MiMedx Group, Inc. (NASDAQ:MDXG) has dismissed its lawsuit against the company, a mere month after it was announced.
    ( Read full version of this press release...)
  • CANTON, MASS. / ORLANDO, FLA. – April 22, 2014
    Organogenesis to Present New Apligraf® and Dermagraft® Data at the Symposium on Advanced Wound Care and Wound Healing Society Annual Meeting
    This week, Organogenesis Inc. will present new mechanisms of action data from an Apligraf® clinical study and in vitro / pre-clinical data evaluating mechanisms of healing for Dermagraft® at the Symposium on Advanced Wound Care (SAWC) / Wound Healing Society (WHS) Spring 2014 meeting in Orlando, Fla.
    ( Read full version of this press release...)
  • Canton, Mass. – January 17, 2014
    Organogenesis Inc. Announces Acquisition of Dermagraft® from Shire
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it has purchased the Dermagraft® assets (human fibroblast-derived dermal substitute) from Shire plc (LSE: SHP, NASDAQ: SHPG).
    ( Read full version of this press release...)
  • Canton, Mass. – November 6, 2013
    Organogenesis Launches Fight4MyFeet for Diabetes Patient and Healthcare Provider Communities
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, is launching Fight4MyFeet, an educational program and online resource focused on proper foot hygiene within the diabetic community. Fight4MyFeet offers patients and clinicians tools and strategies to help ensure the best chance of healing a diabetic foot ulcer.
    ( Read full version of this press release...)
  • Canton, Mass. – October 21, 2013
    GINTUIT™ Nominated for Prestigious Prix Galien USA Award.
    The Galien Foundation, a foundation which fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health, has nominated Organogenesis Inc.'s newest FDA approved product, GINTUIT™ (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) for the seventh annual Prix Galien USA Awards in the "Best Biotechnology Product" category.
    ( Read full version of this press release...)
  • Canton, Mass. / New Orleans, LA – May 22, 2013
    Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers.
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy) demonstrating the significant healthcare resource and economic burden that diabetic foot ulcers (DFU) and venous leg ulcers (VLU) place upon the US healthcare system.
    ( Read full version of this press release...)
  • Canton, Mass. – May 6, 2013
    Organogenesis Presents Data at SAWC 2013 Demonstrating Apligraf® Speed and Incidence of Wound Closure in Real-world Analysis of Venous Leg Ulcer Patients.
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today key findings demonstrating the speed and incidence of wound closure for venous leg ulcer (VLU) patients who were treated with Apligraf®. The oral presentation of the abstract, titled "A Retrospective Analysis of a Bilayered Living Cellular Construct and a Porcine Collagen Wound Dressing for the Treatment of Venous Leg Ulcers in a Real World Setting," was presented at the Symposium of Advanced Wound Care Meeting (SAWC Spring) in Denver, Colorado by Nathan Parsons, director of medical affairs, Organogenesis Inc.
    ( Read full version of this press release...)
  • Canton, Mass. – April 30, 2013
    Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting.
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it will present new Apligraf® comparative effectiveness data and chronic wound burden of illness economic analyses at the Symposium of Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Meeting (SAWC Spring/WHS) held May 1-5, 2013 in Denver, Colorado. Organogenesis is also supporting a WHS research award program and will feature Apligraf at booth #707.
    ( Read full version of this press release...)
  • Canton, MA. – August 6, 2012
    Organogenesis Announces Annual College Scholarship Award Winner.
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, is announcing Symone Isaac-Wilkins as the winner of its annual college scholarship. The award honors the achievement of a graduating Canton High School senior interested in pursuing a career in medicine, life sciences research or biomedical engineering.
    ( Read full version of this press release...)
  • Canton, Mass. – Tuesday, March 27, 2012
    Organogenesis CEO Geoff MacKay Elected Chairman of MassBio board of Directors.
    Today MassBio members elected Geoff MacKay, president & CEO of regenerative medicine leader Organogenesis Inc., as chairman of the board of directors at the 2012 MassBio Annual Meeting.
    ( Read full version of this press release...)
  • Canton, Mass. – Monday, March 12, 2012
    Organogenesis Inc. Announces FDA Approval of Gintuit™ for Oral Soft Tissue Regeneration.
    Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT™ (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue).
    ( Read full version of this press release...)